Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
PMID: 17876005
2007
Antimicrobial agents and chemotherapy
Abstract: We describe an unusual pathway of human immunodeficiency virus type 1 reverse transcriptase resistance during therapy with tenofovir-emtricitabine, characterized initially by the mutations K70E and M184V and later by K70G and M184V, with the two mutations coexisting on the same viral genome.
High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004.
Abstract: Using a highly sensitive allele-specific polymerase chain reaction assay we detected the M184V mutation for lamivudine resistance in plasma from 9.4% of HIV-1-infected pregnant women enrolled in the Women and Infant Transmission Study between 1998 and 2004.
The anti-HIV antiviral activity of entecavir: the loss of a trusted friend?
Abstract: Detailed analysis showed that in one of these patients, entecavir monotherapy led to an accumulation of HIV-1 variants with the lamivudine-resistant mutation, M184V.
Abstract: In vitro experiments showed that M184V confers resistance to entecavir.
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
Abstract: M184I/V disappeared in patients in whom 3TC was stopped but ddI continued.
Abstract: Although M184I/V may reduce the genetic barrier of ddI for mutations such as K65R and L74V, the lack of re-emergence of M184I/V in the minor quasispecies of most patients who failed ddI suggests that M184I/V was not a preferred route to ddI resistance in our patient population.
Abstract: CONCLUSIONS: Minor HIV-1 strains may harbour M184I/V in patients failing ddI therapy, despite direct sequencing showing wild-type virus.
Abstract: MATERIALS AND METHODS: Fourteen 3TC-experienced patients who, after switching therapy to a ddI regimen, had a new failure without M184I/V i
Revertant multiresistant HIV in chronically infected drug naive patients: when baseline resistance testing is not enough.
PMID: 17945056
2007
International journal of STD & AIDS
Abstract: Interestingly, his viral load remained high even in the presence of the M184V mutation.
High frequency of drug resistance mutations in human immunodeficiency virus type 1-infected Korean patients treated with HAART.
PMID: 17961108
2007
AIDS research and human retroviruses
Abstract: The most frequently observed mutation was M184V (24.3%, 9/37).
High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India.
PMID: 17961120
2007
AIDS research and human retroviruses
Abstract: We report one or more HIV resistance mutations in 81.81% of the 33 antiretroviral treatment-experienced study participants with evidence of virologic failure, with M184V being the most commonly observed resistance mutation (69.7%).
Synthesis, anti-HIV activity, and resistance profiles of ribose modified nucleoside phosphonates.
Abstract: The most potent analog [5-(6-amino-purin-9-yl)-2,5-dihydro-furan-2-yloxymethyl]-phosphonic acid (d4AP) demonstrated a HIV EC(50)=2.1 microM, and the most favorable resistance profile against HIV-1 variants with K65R, M184V or multiple thymidine analog mutations in RT.
Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
Abstract: M184V was marginally associated with virologic success (HR: 1.34, 95% CI: 0.94-1.90, p = 0.10 vs no M184V), whilst the number of TAMs was not associated.
Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice.
Discussion: Single mutations in reverse transcriptase (RT) confer resistance to nucleoside RT inhibitors (M184V, K65R) and nonnucleoside RT inhibitors (Y181C) without significantly compromising viral fitness, yet these drugs are used in most antiretroviral regimens.
HIV mutation literature information.
PMID: 
2007
Antimicrobial agents and chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT